Orasis Pharmaceuticals is a technology company.
Orasis Pharmaceuticals has raised $111.0M across 3 funding rounds.
Orasis Pharmaceuticals has raised $111.0M in total across 3 funding rounds.
Orasis Pharmaceuticals has raised $111.0M in total across 3 funding rounds.
Orasis Pharmaceuticals's investors include Sequoia Capital Israel, Rafi Gidron.
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on developing innovative eye care solutions, primarily targeting presbyopia, the age-related loss of near vision affecting nearly two billion people worldwide. Their flagship product, Qlosi™ (pilocarpine HCl ophthalmic solution) 0.4%, is an FDA-approved prescription eye drop designed to improve near vision as an alternative to reading glasses. Orasis serves adults experiencing presbyopia, addressing a widespread vision problem with a novel, non-invasive treatment option. The company is gaining momentum through regulatory approval and strategic backing by prominent life science investors, positioning itself as a disruptor in the eyecare pharmaceutical market[1][2].
Founded with a purpose-driven mission to challenge conventional thinking in vision care, Orasis Pharmaceuticals was established by a team of industry veterans and eye care professionals led by CEO Elad Kedar, who has over 20 years of pharmaceutical leadership experience. The idea emerged from the unmet need for effective, easy-to-use treatments for presbyopia beyond traditional corrective lenses. Early traction includes FDA approval of Qlosi™ and securing funding from a diverse group of sophisticated investors such as Arboretum Ventures, Johnson & Johnson Innovation – JJDC, Catalio Capital Management, and Visionary Ventures, reflecting confidence in Orasis’s innovative approach and growth potential[1][3][4].
Orasis is riding the growing trend of pharmaceutical innovation targeting age-related vision disorders, a market driven by demographic shifts such as aging populations worldwide. The timing is favorable due to increasing demand for non-invasive, drug-based therapies that improve quality of life without surgery or cumbersome devices. Market forces include rising presbyopia prevalence, patient preference for convenient treatments, and advances in ophthalmic drug formulation. Orasis’s success could influence the broader eyecare ecosystem by validating pharmacological approaches to vision correction and encouraging further innovation in ophthalmic pharmaceuticals[1][2].
Looking ahead, Orasis Pharmaceuticals is poised to expand its market presence by scaling commercial distribution of Qlosi™ and potentially developing additional ophthalmic products addressing other vision impairments. Trends shaping their journey include increasing adoption of pharmaceutical treatments for eye conditions, regulatory support for innovative therapies, and growing patient awareness. Their influence may evolve as a pioneer in reshaping vision care paradigms, potentially inspiring new drug-based solutions and partnerships within the eyecare and pharmaceutical industries[1][4]. This aligns with their founding vision to disrupt conventional thinking and improve vision possibilities globally.
Orasis Pharmaceuticals has raised $111.0M across 3 funding rounds. Most recently, it raised $68.0M Series D in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $68.0M Series D | Sequoia Capital Israel, Rafi Gidron | |
| Sep 1, 2020 | $30.0M Series C | Sequoia Capital Israel, Rafi Gidron | |
| Jun 1, 2018 | $13.0M Series B | Sequoia Capital Israel, Rafi Gidron |